Research Projects & Grants

Federal

  • SWOG-A011106:ALTernate approaches for clinical stage II or III estrogen receptor positive breast cancer NeoAdjuvant TreEatment (ALTERNATE) in postmenopausal women: a phase III study, Role: Investigator, Southwest Oncology Group, (07/2026 - 07/2027) Status: Approved
  • Southwest Oncology Group (SWOG) Protocol N063D/BIG2-06-ALTTO - Adjuvant lapatinib and/or trastuzumab treatment optimisation study. A randomized, multi-center, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer, Role: Investigator, Southwest Oncology Group, (03/2026 - 03/2027) Status: Approved
  • SWOG S1418/BR006: A randomized phase III trial to evaluate the efficacy and safety of MK-3457 (Pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer with = 1 cm residual invasive cancer or positive lymph nodes (ypN+) after neoadjuvant chemotherapy, Role: Investigator, Southwest Oncology Group, (12/2025 - 12/2026) Status: Approved
  • SWOG-S1207: Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of EVEROLIMUS in patients with high-risk hormone receptor-positive AND HER2/neu negative breast cancer e3 breast cancer study - evaluating everolimus with endocrine therapy, Role: Investigator, Southwest Oncology Group, (11/2025 - 11/2026) Status: Approved
  • SWOG-S0820: A double blind placebo-controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers in patients with stage 0-III colon cancer, phase III - preventing adenomas of the colon with eflornithine and sulindac (PACES), Role: Investigator, Southwest Oncology Group, (08/2026 - 08/2027) Status: Approved
  • SWOG E1697: Phase III randomized study of four weeks high dose IFN-a2b in stage T2bN0, T3a-bN0, and T1-4, N1a2a (microscopic) melanoma, Role: Investigator, Southwest Oncology Group, (01/2026 - 01/2027) Status: Approved
  • SWOG A151216: adjuvant lung cancer enrichment marker identification and sequencing trial (ALCHEMIST), Role: Investigator, Southwest Oncology Group, (08/2026 - 08/2027) Status: Approved
  • SWOG-A081105: randomized study of Erlotinib VS Observation in patients with completely resected Epidermal Growth Factor Receptor (EGFR) mutant Non-small Cell Lung Cancer (NSCLC), Role: Investigator, Southwest Oncology Group, (07/2026 - 07/2027) Status: Approved
  • SWOG EA5142:adjuvant nivolumab in resected lung cancers (ANVIL) a randomized phase III study of nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancers, Role: Investigator, Southwest Oncology Group, (11/2025 - 11/2026) Status: Approved
  • SWOG - PACCT-1: Program of the assessment of clinical tests (PACCT-1): Trial assigning individualized options for treatment: the TAILORx trial, Role: Investigator, Eastern Cooperative Oncology Group, (11/2025 - 11/2026) Status: Approved
  • SWOG-S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and HER-2 negative breast cancer with recurrence score (RS) of 25 or less. RxPONDER: A clinical trial Rx for positive node, endocrine responsive breast cancer, Role: Investigator, Southwest Oncology Group, (11/2025 - 11/2026) Status: Approved
  • Southwest Oncology Group (SWOG) S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors, Role: Investigator, Southwest Oncology Group, (11/2025 - 11/2026) Status: Approved

For Profit Organization

  • Castle Biosciences Inc. CBl-2019-SLNBprosp-001: DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes DECIDE, Role: Investigator, Castle Biosciences, Inc., (11/2020) Status: Approved
  • Amgen Inc., 20190135: A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of AMG 510 (plNN Sotorasib) in Combination with Panitumumab and in Combination with Panitumumab and Chemotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H), Role: Investigator, Amgen, Inc., (05/2026 - 05/2027) Status: Approved
  • RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS (MUT) NSCLC, Role: Investigator, Revolution Medicines, Inc., (01/2026 - 01/2027) Status: Approved
  • J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence, Role: Regulatory Coordinator, Eli Lilly & Co., (05/2026 - 05/2027) Status: Approved
  • TCBIO-001-0710: The Caris Biorepository Research Protocol, Role: Investigator, Caris MPI, Inc., (04/2026) Status: Approved

Internal

  • LLU Cancer Center biospecimen laboratory - specimens collection protocol, Role: Investigator, LLU Cancer Center, (09/2026 - 09/2027) Status: Approved